The online reference source for the interventional NeuroRadiology and NeuroSurgery community
Montpellier Fr. - Sim&Cure, a medical technology company focuses on the development and commercialization of a simulation software, Sim&Size®, for devices treating patients with cerebral aneurysm. The simulation can be done during the intervention or pre-intervention.
December 6, 2017
ALISO VIEJO, CA - MicroVention, a wholly owned subsidiary of Terumo Corporation and a global neurovascular company, today announced that the Grand Opening of its New Innovation Center was held on Monday, September 25. The opening of the new facility, located in the heart of the Summit Office Campus, also signifies the Company's official return to Aliso Viejo: MicroVention was founded there in 1997, originally occupying buildings very close to the new location and is also commemorating their 20 year anniversary as a Company.
September 28, 2017
Colorado Springs, Co. – Johnson & Johnson Medical Devices Companies* today introduced CERENOVUS,** its new neurovascular business, at the Society of NeuroInterventional Surgery (SNIS) 14th Annual Meeting. CERENOVUS, a name derived from the Latin words for ‘new’ and ‘brain’, will focus on delivering innovative therapies for hemorrhagic and ischemic stroke patients.
August 1, 2017
On June 13-15, the 20th “Live International Neuroradiology and Neurosurgery Course” took place. Specialists of neuroradiology met at the Carrousel du Louvre in Paris, to discuss live cases which were presented from all over the world. phenox has sponsored the LINNC for years. This year was the first time phenox was a silver sponsor of the meeting and was present with a booth, a training area as well as its own symposium.
July 10, 2017
Kalamazoo, Michigan, USA – Results from the DAWN Trial were presented today at the European Stroke Organisation Conference (ESOC), providing compelling evidence that more patients suffering ischemic stroke may benefit from endovascular treatment. While previous randomized clinical trials have proven the benefit of stent retrievers within six hours of stroke onset, the DAWN Trial is the first to evaluate the late‐window and wake‐up stroke patient population.
May 16, 2017
Second acquisition in months demonstrates commitment to addressing unmet needs in stroke
April 10, 2017
Company closes additional Series A financing
March 21, 2017